Neomycin And Polymyxin B Sulfates And Hydrocortisone

Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone


Sandoz Inc
Human Prescription Drug
NDC 61314-641
Neomycin And Polymyxin B Sulfates And Hydrocortisone also known as Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone is a human prescription drug labeled by 'Sandoz Inc'. National Drug Code (NDC) number for Neomycin And Polymyxin B Sulfates And Hydrocortisone is 61314-641. This drug is available in dosage form of Suspension. The names of the active, medicinal ingredients in Neomycin And Polymyxin B Sulfates And Hydrocortisone drug includes Hydrocortisone - 10 mg/mL Neomycin Sulfate - 3.5 mg/mL Polymyxin B Sulfate - 10000 [USP'U]/mL . The currest status of Neomycin And Polymyxin B Sulfates And Hydrocortisone drug is Active.

Drug Information:

Drug NDC: 61314-641
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Neomycin And Polymyxin B Sulfates And Hydrocortisone
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Sandoz Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Suspension
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:HYDROCORTISONE - 10 mg/mL
NEOMYCIN SULFATE - 3.5 mg/mL
POLYMYXIN B SULFATE - 10000 [USP'U]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:OPHTHALMIC
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 09 May, 2003
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 25 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA062874
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Sandoz Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:204874
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0361314641755
UPC stands for Universal Product Code.
NUI:N0000175576
N0000175450
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:WI4X0X7BPJ
057Y626693
19371312D4
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:Corticosteroid Hormone Receptor Agonists [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:Corticosteroid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class:Aminoglycoside Antibacterial [EPC]
Aminoglycosides [CS]
Corticosteroid Hormone Receptor Agonists [MoA]
Corticosteroid [EPC]
Polymyxin-class Antibacterial [EPC]
Polymyxins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
61314-641-757.5 mL in 1 BOTTLE, PLASTIC (61314-641-75)09 May, 2003N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.
Other medicines with the same generic name

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Suspension/ Drops
A-S Medication Solutions
NDC: 50090-0431

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Suspension
Sandoz Inc
NDC: 61314-641

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Suspension/ Drops
Bausch & Lomb Incorporated
NDC: 24208-635

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Suspension/ Drops
Preferred Pharmaceuticals, Inc.
NDC: 68788-9924

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Suspension/ Drops
Proficient Rx LP
NDC: 63187-308

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Suspension
Sandoz Inc.
NDC: 61314-645

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Solution
NuCare Pharmaceuticals,Inc.
NDC: 68071-2735

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Solution
Sandoz Inc
NDC: 61314-646

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Suspension
Preferred Pharmaceuticals Inc.
NDC: 68788-8130

Neomycin And Polymyxin B Sulfates And Hydrocortisone


Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Solution
Proficient Rx LP
NDC: 63187-568

Product Elements:

Neomycin and polymyxin b sulfates and hydrocortisone neomycin sulfate, polymyxin b sulfate and hydrocortisone neomycin sulfate neomycin polymyxin b sulfate polymyxin b hydrocortisone hydrocortisone thimerosal cetyl alcohol glyceryl monostearate mineral oil polyoxyl 40 stearate propylene glycol sulfuric acid water

Indications and Usage:

Indications and usage neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye [see clinical pharmacology: microbiology ]. the particular
anti-infective drugs in this product are active against the following common bacterial eye pathogens: staphylococcus aureus , escherichia coli , haemophilus influenzae , klebsiella/enterobacter species, neisseria species, and pseudomonas aeruginosa . the product does not provide adequate coverage against serratia marcescens and streptococci, including streptococcus pneumoniae .

Warnings:

Warnings not for injection into the eye. neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension should never be directly introduced into the anterior chamber of the eye. prolonged use of corticosteroids may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. in those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. in acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection. if these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in uncooperative patients. corticosteroids should be used with caution in the presence of glaucoma. the use of corti
costeroids after cataract surgery may delay healing and increase the incidence of filtering blebs. use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). employment of corticosteroid medication in the treatment of herpes simplex requires great caution. topical antibiotics, particularly, neomycin sulfate, may cause cutaneous sensitization. a precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. the manifestations of sensitization to topical antibiotics are usually itching, reddening, and edema of the conjunctiva and eyelid. a sensitization reaction may manifest simply as a failure to heal. during long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. symptoms usually subside quickly on withdrawing the medication. application of products containing these ingredients should be avoided for the patient thereafter [see precautions: general ] .

Dosage and Administration:

Dosage and administration one or two drops in the affected eye every 3 or 4 hours, depending on the severity of the condition. the suspension may be used more frequently if necessary. not more than 20 ml should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in precautions above.

Contraindications:

Contraindications neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension is contraindicated in most viral diseases of the cornea and conjunctiva including: epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension is also contraindicated in individuals who have shown hypersensitivity to any of its components. hypersensitivity to the antibiotic component occurs at a higher rate than for other components.

Adverse Reactions:

Adverse reactions adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. the exact incidence is not known. reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitization reactions including itching, swelling, and conjunctival erythema [see warnings ]. more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. the reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (iop) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. secondary infection the development of secondary infection has occurred after use of combinations containing corticosteroids and antimicrobials. fungal and viral infections of the cornea are particularly
prone to develop coincidentally with long-term applications of a corticosteroid. the possibility of fungal invasion must be considered in any persistent corneal ulceration where corticosteroid treatment has been used. local irritation on instillation has also been reported. to report suspected adverse reactions, contact sandoz inc. at 1-800-525-8747 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Use in Pregnancy:

Pregnancy teratogenic effects pregnancy category c. corticosteroids have been found to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 -18 of gestation and in mice when applied topically at a concentration of 15% on days 10 -13 of gestation. there are no adequate and well-controlled studies in pregnant women. neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

Pediatric use safety and effectiveness in pediatric patients have not been established.

Geriatric Use:

Geriatric use no overall differences in safety or effectiveness have been observed between elderly and younger patients.

Description:

Description neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use. each ml contains: actives: neomycin sulfate (equivalent to 3.5 mg neomycin base), polymyxin b sulfate equivalent to 10,000 polymyxin b units, and hydrocortisone 10 mg (1%). preservative: thimerosal 0.001%. inactives: cetyl alcohol, glyceryl monostearate, mineral oil, polyoxyl 40 stearate, propylene glycol, sulfuric acid (to adjust ph) and water for injection. neomycin sulfate is the sulfate salt of neomycin b and c, which are produced by the growth of streptomyces fradiae waksman (fam. streptomycetacae). it has a potency equivalent to not less than 600 μg of neomycin standard per mg, calculated on an anhydrous basis. its structural formula are: neomycin b (r 1 =h, r 2 =ch 2 nh 2 ) neomycin c (r 1 =ch 2 nh 2 , r 2 =h) polymyxin b sulfate is the sulfate salt of polymyxin, b1 and b2, which are produced by the growth of bacillus polymyxa (prazmowski) migula (fam. bacillaceae). it has a potency of not less than 6,000 polymyxin b units per mg calculated on an anhydrous basis. its structural formula are: hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20 dione, is an anti-inflammatory hormone. its structural formula is: neomycin polymyxin name hydrocortisone-chemical

Clinical Pharmacology:

Clinical pharmacology corticosteroids suppress the inflammatory response to a variety of agents, and they probably delay or slow healing. since corticosteroids may inhibit the body's defense mechanism against infection, concomitant antimicrobial drugs may be used when this inhibition is considered to be clinically significant in a particular case. when a decision to administer both a corticosteroid and antimicrobials is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of all drugs is administered. when each type of drug is in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained. the relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle. microbiology the anti-infective components in neomycin and polymyxin b sulfates and hydrocortisone ophth
almic suspension are included to provide action against specific organisms susceptible to it. neomycin sulfate and polymyxin b sulfate are active in vitro against susceptible strains of the following microorganisms: staphylococcus aureus , escherichia coli , haemophilus influenzae , klebsiella/enterobacter species, neisseria species, and pseudomonas aeruginosa . the product does not provide adequate coverage against serratia marcescens and streptococci, including streptococcus pneumoniae [see indications and usage ].

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin b sulfate. treatment of cultured human lymphocytes in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentrations (80 ug/ml) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity or mutagenicity attributable to oral administration of corticosteroids. long-term animal studies have not been performed to evaluate the carcinogenic potential of topical corticosteroids. studies to determine mutagenicity with hydrocortisone have revealed negative results. use of corticosteroid medication in the treatment of herpes simplex requires great caution. polymyxin b has been reported to impair the motility of equine sperm, but its effects on male or female fertility
are unknown. long-term animal studies have not been performed to evaluate the effect on fertility of topical corticosteroids.

How Supplied:

How supplied neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension is available in a bottle containing 7.5 ml. ndc 61314-641-75 shake well before using. store at 20° to 25°c (68° to 77°f).

Information for Patients:

Information for patients patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface. the use of this product by more than one person may spread infection. patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. serious damage to the eye and subsequent loss of vision may result from using contaminated products [see precautions: general ]. if the condition persists or gets worse, or if a rash or allergic reaction develops, the patient should be advised to stop use and consult a physician. do not use this product if you are allergic to any of the listed ingredients. keep tightly closed when not in use. keep out of reach of children.

Package Label Principal Display Panel:

Principal display panel ndc 61314-641-75 neomycin and polymyxin b sulfates and hydrocortisone ophthalmic suspension, usp for topical ophthalmic use only rx only sterile 7.5 ml sandoz 7.5mlcarton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.